SIU Academy Bench to Bedside

This event was submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and is awaiting CME approval.

SIU ACADEMY BENCH TO BEDSIDE URO-ONCOLOGY GU CANCER TRIAD

7 November 0800-1130 AM EST – Bladder & Kidney Cancers

8 November 0800-1100 AM EST – Prostate Cancer

Learning Objectives

At the end of this programme, participants will be able to:

• Evaluate the benefits and risks of various treatment options across the treatment continuum in BCa, RCC, and PCa.
• Discuss strategies for managing oligometastatic disease.
• Evaluate the role of imaging or biomarkers vs. biopsy in active surveillance for localized prostate cancer.
• Discuss strategies to identify and manage adverse events related to immunotherapy.
• Evaluate the role of immunotherapy vs. VEGF-targeted therapies for RCC.
• Discuss the importance of personalised medicine, based on costs and patient preference, while minimizing toxicity and maximising efficacy.

 Scientific Programme Committee

• Peter Black (Chair), Canada
• Christopher Evans, United States
• Peter Hammerer, Germany
• Simon Tanguay, Canada

 Faculty

• Jason Abel, United States
• Arjun Balar, United States
• Alberto Bossi, France
• Marc Dall’Era, United States
• Alex de la Taille, France
• Shin Egawa, Japan
• Martin Gleave, Canada
• Karim Fizazi, France
• Kilian Gust, Austria
• Jose Karam, United States
• Wassim Kassouf, Canada
• Christian Kollmannsberger, Canada
• Dan Lin, United States
• Axel Merseburger, Germany
• Todd Morgan, United States
• Peter Mulders, The Netherlands
• Thomas Powles, United Kingdom
• Brian Rini, United States
• Morgan Roupret, France
• Fred Saad, Canada
• Srikala Sridhar, Canada
• Derya Tilki, Germany
• Tilman Todenhöfer, Germany
• Hiro Uemura, Japan

More information: https://www.siu-urology.org/events/b2bgu2020

Registration: https://www.siu-urology.org/academy/b2b-uro-oncology-gu-cancer-triad-nov-7-8-2020

Welcome Video: https://www.youtube.com/watch?v=ZmfzeY1IsDQ&t